Cor Vasa 2009, 51(2):131-135 | DOI: 10.33678/cor.2009.032

What are our chances to reach the new LDL-cholesterol treatment goals in secondary prevention?

Otto Mayer jr.
Centrum preventivní kardiologie II. interní kliniky, Univerzita Karlova Praha - Lékařská fakulta a Fakultní nemocnice v Plzni, Plzeň, Česká republika

A number of clinical trials have shown patients with overt coronary heart disease may benefit from more aggressive lowering of LDL-cholesterol to 2 mmol/L, or even lower. The current guidelines define this concentration of LDL as the optional treatment goal. We sought to determine to what extent it is feasible to reach this new target in clinical practice and to assess the costs involved.

Keywords: LDL-cholesterol; Treatment goals; Secondary prevention; Guidelines

Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mayer O. What are our chances to reach the new LDL-cholesterol treatment goals in secondary prevention? Cor Vasa. 2009;51(2):131-135. doi: 10.33678/cor.2009.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehab 2007;14 (Suppl 2):E1-E113. Go to original source... Go to PubMed...
    2. Vaverková H, Soška V, Rosolová H, et al. Doporučení pro diagnostiku a léčbu dyslipidemií. Vnitř Lék 2007;53:181-97. Go to PubMed...
    3. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45. Go to original source... Go to PubMed...
    4. Mayer O jr., Šimon J, Galovcová M, a spol. Úroveň sekundární prevence ischemické choroby srdeční u českách pacientů ve studii EUROASPIRE III. Cor Vasa 2008;50:156-62. Go to original source...
    5. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-509. Go to original source... Go to PubMed...
    6. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62. Go to original source... Go to PubMed...
    7. Hunninghake D, Insull W Jr, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001;158:407-16. Go to original source...
    8. Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001;87:476-9. Go to original source...
    9. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-72. Go to original source... Go to PubMed...
    10. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95: 120-2. Go to original source... Go to PubMed...
    11. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61. Go to original source... Go to PubMed...
    12. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462-8. Go to original source... Go to PubMed...
    13. Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidemia. Diabetes Res Clin Pract 2004;64:137-51. Go to original source... Go to PubMed...
    14. Kastelein JJ, Akdim F, Stroes ES, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43. Go to original source... Go to PubMed...
    15. Cruz-Fernandez J, Bedarida G, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005;59:619-27. Go to original source... Go to PubMed...
    16. Ballantyne C, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-73. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes